Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased to announce their acceptance to give an oral presention at the International Rett Syndrome Foundation (IRSF) Scientific Meeting, taking place June 9-11th, 2025.
Dr. Mark Williams, Chief Science Officer of Marvel, will present on behalf of the Company and its research collaborators, Dr. Julie Le Merrer and Dr. Jérôme Becker from the iBraiN Institute in Tours, France. The presentation will highlight Marvel's most recent preclinical studies of MB-204 in Rett Syndrome and Autism Spectrum Disorder (ASD). Drs. Le Merrer and Becker are leading experts in in vivo models of neuropsychiatric disorders, and their collaboration with Marvel has produced promising preclinical data for MB-204.
The IRSF Rett Syndrome Scientific Meeting is a premier international forum for the latest advancements in Rett research, connecting scientists, clinicians, and patient advocates working to accelerate the development of effective treatments. Hosted by the International Rett Syndrome Foundation, the event promotes collaboration and the translation of breakthrough research into clinical solutions.
"We are honored to present at the IRSF Rett Syndrome Scientific Meeting-one of the most important gatherings for advancing treatment and research in Rett Syndrome," said Dr. Mark Williams, Chief Science Officer of Marvel. "We're grateful to our collaborators for their partnership and look forward to sharing these compelling findings with the community."
"Our team is committed to delivering innovative therapies to address unmet needs in neurological and neurodevelopmental disorders," added Rod Matheson, CEO of Marvel. "We look forward to building new relationships at this meeting and advancing MB-204 toward clinical trials."
Marvel and its collaborators intend to publish the full study results in a peer-reviewed scientific journal. In parallel, Marvel is preparing to submit an application for Orphan Drug Designation for MB-204 as a treatment for Rett syndrome with the U.S. FDA.
About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary- based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline, the only clinically approved adenosine A2a antagonist. A signicant and growing body of scientic evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.
Contact Information:
Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer Tel: 403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is dened in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identied by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the lings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualied by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248637
SOURCE: Marvel Biosciences Corp.
